---
document_datetime: 2025-12-02 05:53:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-krka.html
document_name: febuxostat-krka.html
version: success
processing_time: 0.1151343
conversion_datetime: 2025-12-24 08:16:43.456947
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Febuxostat Krka

[RSS](/en/individual-human-medicine.xml/67175)

##### Authorised

This medicine is authorised for use in the European Union

febuxostat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Febuxostat Krka](#news-on)
- [More information on Febuxostat Krka](#more-information-on-febuxostat-krka-1553)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Febuxostat Krka is a medicine used to treat adults with long-term hyperuricaemia (high levels of uric acid or 'urate' in the blood). Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys. When this happens in the joints and causes pain, it is known as 'gout'. Febuxostat Krka is used in patients who have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi ('stones', larger deposits of urate crystals that can cause joint and bone damage).

Febuxostat Krka is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are receiving chemotherapy (medicines to treat cancer) and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys).

Febuxostat Krka contains the active substance febuxostat and is a 'generic medicine'. This means that Febuxostat Krka contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Adenuric.

Expand section

Collapse section

## How is Febuxostat Krka used?

Febuxostat Krka is available as tablets (80 and 120 mg) and can only be obtained with a prescription.

For the treatment of long-term hyperuricaemia, the recommended dose of Febuxostat Krka is 80 mg once a day. This usually reduces blood uric acid levels within 2 weeks, but the dose can be increased to 120 mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after 2 to 4 weeks. Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first 6 months of treatment with Febuxostat Krka. Febuxostat Krka treatment should not be stopped if an attack of gout occurs.

For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, the recommended dose is 120 mg once a day. Febuxostat Krka should be started 2 days before chemotherapy and continued for at least 7 days.

For more information about using Febuxostat Krka, see the package leaflet or contact your doctor or pharmacist.

## How does Febuxostat Krka work?

The active substance in Febuxostat Krka, febuxostat, reduces the formation of uric acid. It works by blocking an enzyme called xanthine oxidase, which is needed to make uric acid in the body. By reducing the production of uric acid, Febuxostat Krka can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up. This can reduce the symptoms of gout. Keeping uric acid levels low for long enough can also shrink tophi. In patients who are on chemotherapy a reduction in uric acid levels is expected to reduce the risk of tumour lysis syndrome.

## How has Febuxostat Krka been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Adenuric, and do not need to be repeated for Febuxostat Krka.

As for every medicine, the company provided studies on the quality of Febuxostat Krka. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Febuxostat Krka?

Because Febuxostat Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Febuxostat Krka authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Febuxostat Krka has been shown to have comparable quality and to be bioequivalent to Adenuric. Therefore, the Agency's view was that, as for Adenuric, the benefit of Febuxostat Krka outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Febuxostat Krka?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Febuxostat Krka have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Febuxostat Krka are continuously monitored. Side effects reported with Febuxostat Krka are carefully evaluated and any necessary action taken to protect patients.

## Other information about Febuxostat Krka

Febuxostat Krka received a marketing authorisation valid throughout the EU on 28 March 2019.

Febuxostat Krka : EPAR - Medicine overview

Reference Number: EMA/110881/2019

English (EN) (76.46 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/overview/febuxostat-krka-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-553)

български (BG) (124.17 KB - PDF)

**First published:**

29/03/2019

[View](/bg/documents/overview/febuxostat-krka-epar-medicine-overview_bg.pdf)

español (ES) (101.2 KB - PDF)

**First published:**

29/03/2019

[View](/es/documents/overview/febuxostat-krka-epar-medicine-overview_es.pdf)

čeština (CS) (119.35 KB - PDF)

**First published:**

29/03/2019

[View](/cs/documents/overview/febuxostat-krka-epar-medicine-overview_cs.pdf)

dansk (DA) (100.41 KB - PDF)

**First published:**

29/03/2019

[View](/da/documents/overview/febuxostat-krka-epar-medicine-overview_da.pdf)

Deutsch (DE) (101.27 KB - PDF)

**First published:**

29/03/2019

[View](/de/documents/overview/febuxostat-krka-epar-medicine-overview_de.pdf)

eesti keel (ET) (98.12 KB - PDF)

**First published:**

29/03/2019

[View](/et/documents/overview/febuxostat-krka-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.64 KB - PDF)

**First published:**

29/03/2019

[View](/el/documents/overview/febuxostat-krka-epar-medicine-overview_el.pdf)

français (FR) (101.73 KB - PDF)

**First published:**

29/03/2019

[View](/fr/documents/overview/febuxostat-krka-epar-medicine-overview_fr.pdf)

hrvatski (HR) (114.12 KB - PDF)

**First published:**

29/03/2019

[View](/hr/documents/overview/febuxostat-krka-epar-medicine-overview_hr.pdf)

italiano (IT) (100.63 KB - PDF)

**First published:**

29/03/2019

[View](/it/documents/overview/febuxostat-krka-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (118.37 KB - PDF)

**First published:**

29/03/2019

[View](/lv/documents/overview/febuxostat-krka-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (119.2 KB - PDF)

**First published:**

29/03/2019

[View](/lt/documents/overview/febuxostat-krka-epar-medicine-overview_lt.pdf)

magyar (HU) (114.3 KB - PDF)

**First published:**

29/03/2019

[View](/hu/documents/overview/febuxostat-krka-epar-medicine-overview_hu.pdf)

Malti (MT) (120.03 KB - PDF)

**First published:**

29/03/2019

[View](/mt/documents/overview/febuxostat-krka-epar-medicine-overview_mt.pdf)

Nederlands (NL) (101.06 KB - PDF)

**First published:**

29/03/2019

[View](/nl/documents/overview/febuxostat-krka-epar-medicine-overview_nl.pdf)

polski (PL) (119.56 KB - PDF)

**First published:**

29/03/2019

[View](/pl/documents/overview/febuxostat-krka-epar-medicine-overview_pl.pdf)

português (PT) (100.76 KB - PDF)

**First published:**

29/03/2019

[View](/pt/documents/overview/febuxostat-krka-epar-medicine-overview_pt.pdf)

română (RO) (117.85 KB - PDF)

**First published:**

29/03/2019

[View](/ro/documents/overview/febuxostat-krka-epar-medicine-overview_ro.pdf)

slovenčina (SK) (118.77 KB - PDF)

**First published:**

29/03/2019

[View](/sk/documents/overview/febuxostat-krka-epar-medicine-overview_sk.pdf)

slovenščina (SL) (114.04 KB - PDF)

**First published:**

29/03/2019

[View](/sl/documents/overview/febuxostat-krka-epar-medicine-overview_sl.pdf)

Suomi (FI) (99.4 KB - PDF)

**First published:**

29/03/2019

[View](/fi/documents/overview/febuxostat-krka-epar-medicine-overview_fi.pdf)

svenska (SV) (100.2 KB - PDF)

**First published:**

29/03/2019

[View](/sv/documents/overview/febuxostat-krka-epar-medicine-overview_sv.pdf)

Febuxostat Krka : EPAR - Risk-management-plan summary

English (EN) (102.8 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/rmp-summary/febuxostat-krka-epar-risk-management-plan-summary_en.pdf)

## Product information

Febuxostat Krka : EPAR - Product Information

English (EN) (313.47 KB - PDF)

**First published:** 29/03/2019

**Last updated:** 27/03/2025

[View](/en/documents/product-information/febuxostat-krka-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-597)

български (BG) (390.69 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/bg/documents/product-information/febuxostat-krka-epar-product-information_bg.pdf)

español (ES) (321.66 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/es/documents/product-information/febuxostat-krka-epar-product-information_es.pdf)

čeština (CS) (314.66 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/cs/documents/product-information/febuxostat-krka-epar-product-information_cs.pdf)

dansk (DA) (361.92 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/da/documents/product-information/febuxostat-krka-epar-product-information_da.pdf)

Deutsch (DE) (344.16 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/de/documents/product-information/febuxostat-krka-epar-product-information_de.pdf)

eesti keel (ET) (707.02 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/et/documents/product-information/febuxostat-krka-epar-product-information_et.pdf)

ελληνικά (EL) (363.28 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/el/documents/product-information/febuxostat-krka-epar-product-information_el.pdf)

français (FR) (444.11 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/fr/documents/product-information/febuxostat-krka-epar-product-information_fr.pdf)

hrvatski (HR) (338.05 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/hr/documents/product-information/febuxostat-krka-epar-product-information_hr.pdf)

íslenska (IS) (323.47 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/is/documents/product-information/febuxostat-krka-epar-product-information_is.pdf)

italiano (IT) (321.21 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/it/documents/product-information/febuxostat-krka-epar-product-information_it.pdf)

latviešu valoda (LV) (429.35 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/lv/documents/product-information/febuxostat-krka-epar-product-information_lv.pdf)

lietuvių kalba (LT) (320.22 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/lt/documents/product-information/febuxostat-krka-epar-product-information_lt.pdf)

magyar (HU) (378.98 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/hu/documents/product-information/febuxostat-krka-epar-product-information_hu.pdf)

Malti (MT) (422.19 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/mt/documents/product-information/febuxostat-krka-epar-product-information_mt.pdf)

Nederlands (NL) (328.39 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/nl/documents/product-information/febuxostat-krka-epar-product-information_nl.pdf)

norsk (NO) (335.35 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/no/documents/product-information/febuxostat-krka-epar-product-information_no.pdf)

polski (PL) (345.39 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/pl/documents/product-information/febuxostat-krka-epar-product-information_pl.pdf)

português (PT) (333.99 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/pt/documents/product-information/febuxostat-krka-epar-product-information_pt.pdf)

română (RO) (384.27 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/ro/documents/product-information/febuxostat-krka-epar-product-information_ro.pdf)

slovenčina (SK) (351 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/sk/documents/product-information/febuxostat-krka-epar-product-information_sk.pdf)

slovenščina (SL) (318.57 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/sl/documents/product-information/febuxostat-krka-epar-product-information_sl.pdf)

Suomi (FI) (339.4 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/fi/documents/product-information/febuxostat-krka-epar-product-information_fi.pdf)

svenska (SV) (447.76 KB - PDF)

**First published:**

29/03/2019

**Last updated:**

27/03/2025

[View](/sv/documents/product-information/febuxostat-krka-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000258495 26/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Febuxostat Krka : EPAR - All authorised presentations

English (EN) (16.21 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-79)

български (BG) (37.11 KB - PDF)

**First published:**

29/03/2019

[View](/bg/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_bg.pdf)

español (ES) (22.33 KB - PDF)

**First published:**

29/03/2019

[View](/es/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_es.pdf)

čeština (CS) (23.17 KB - PDF)

**First published:**

29/03/2019

[View](/cs/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.57 KB - PDF)

**First published:**

29/03/2019

[View](/da/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.44 KB - PDF)

**First published:**

29/03/2019

[View](/de/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.34 KB - PDF)

**First published:**

29/03/2019

[View](/et/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.26 KB - PDF)

**First published:**

29/03/2019

[View](/el/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_el.pdf)

français (FR) (16.33 KB - PDF)

**First published:**

29/03/2019

[View](/fr/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.05 KB - PDF)

**First published:**

29/03/2019

[View](/hr/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.08 KB - PDF)

**First published:**

29/03/2019

[View](/is/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.25 KB - PDF)

**First published:**

29/03/2019

[View](/it/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.49 KB - PDF)

**First published:**

29/03/2019

[View](/lv/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.85 KB - PDF)

**First published:**

29/03/2019

[View](/lt/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.15 KB - PDF)

**First published:**

29/03/2019

[View](/hu/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.13 KB - PDF)

**First published:**

29/03/2019

[View](/mt/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.71 KB - PDF)

**First published:**

29/03/2019

[View](/nl/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.94 KB - PDF)

**First published:**

29/03/2019

[View](/no/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_no.pdf)

polski (PL) (23.95 KB - PDF)

**First published:**

29/03/2019

[View](/pl/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.64 KB - PDF)

**First published:**

29/03/2019

[View](/pt/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.16 KB - PDF)

**First published:**

29/03/2019

[View](/ro/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (23.92 KB - PDF)

**First published:**

29/03/2019

[View](/sk/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.51 KB - PDF)

**First published:**

29/03/2019

[View](/sl/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.22 KB - PDF)

**First published:**

29/03/2019

[View](/fi/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.04 KB - PDF)

**First published:**

29/03/2019

[View](/sv/documents/all-authorised-presentations/febuxostat-krka-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Febuxostat Krka Active substance febuxostat International non-proprietary name (INN) or common name febuxostat Therapeutic area (MeSH)

- Hyperuricemia
- Gout

Anatomical therapeutic chemical (ATC) code M04AA03

### Pharmacotherapeutic group

Antigout preparations

### Therapeutic indication

Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).

Febuxostat Krka is indicated in adults.

## Authorisation details

EMA product number EMEA/H/C/004773

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

KRKA d.d., Novo mesto

Opinion adopted 31/01/2019 Marketing authorisation issued 28/03/2019 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Febuxostat Krka : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.72 KB - PDF)

**First published:** 27/03/2025

[View](/en/documents/procedural-steps-after/febuxostat-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Febuxostat Krka : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (111.75 KB - PDF)

**First published:** 29/10/2019

**Last updated:** 27/03/2025

[View](/en/documents/procedural-steps-after/febuxostat-krka-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Febuxostat Krka : EPAR - Public assessment report

Reference Number: EMA/123663/2019

English (EN) (781.27 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/assessment-report/febuxostat-krka-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Febuxostat Krka

Adopted

Reference Number: EMA/CHMP/849632/2018

English (EN) (71.03 KB - PDF)

**First published:** 01/02/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-febuxostat-krka_en.pdf)

#### News on Febuxostat Krka

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

#### More information on Febuxostat Krka

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/03/2025

## Share this page

[Back to top](#main-content)